Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
基本信息
- 批准号:8306217
- 负责人:
- 金额:$ 13.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-08-01 至 2013-10-31
- 项目状态:已结题
- 来源:
- 关键词:AML1-ETO fusion proteinAcute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAdultAffectAgeAge FactorsAgingAnimal ModelBiologyCancer BiologyCardiovascular systemCell Differentiation processCell ProliferationCellsChemicalsChromosomal translocationDataDevelopmentDevelopmental BiologyDiseaseDominant-Negative MutationElderlyEmbryoErythropoiesisFishesFoundationsGenesGenetic screening methodGoalsGrowthHeat-Shock ResponseHematological DiseaseHematopoieticHematopoietic SystemHematopoietic stem cellsHumanHuman CharacteristicsIn VitroIncidenceLeukemic CellMalignant NeoplasmsMicroarray AnalysisModelingMolecular BiologyMutationMyeloid CellsMyeloid LeukemiaMyelopoiesisMyeloproliferative diseaseOncogenesOutcomePathogenesisPatientsPhenotypeRUNX1 geneResearchResearch PersonnelResistanceRoleSupervisionSurvival RateTestingTherapeuticToxic effectTransgenic OrganismsTreatment outcomeWhole OrganismWorkZebrafishage groupage relatedchemical geneticsgenome-wideimmune functionin vivoinsightleukemiamalignant phenotypemutantnovelnovel therapeuticsolder patientprognosticprogramspromoterresearch studyresponsesmall moleculet(821)(q22q22)therapeutic targettool
项目摘要
DESCRIPTION (provided by applicant): Acute myelogenous leukemia (AML) is a prevalent, deadly disease in older adults. Unlike the incidence rate of acute lymphoblastic leukemia (ALL) which stays pretty much the same among people of varying age groups, the incidence rate of AML shows a dramatic increase with increased age, suggesting a strong association between age and AML pathogenesis. The proposed research aims to (1) determine how two of the common mutations found in AML patients contribute to AML pathogenesis; (2) identify age-dependent factors that contribute to AML pathogenesis; and (3) validate potential, novel therapeutics against AML. The experiments will utilize various unique zebrafish models enabling inducible expression of the human oncogenes. The zebrafish has emerged as a powerful vertebrate model organism because it is highly amenable to both genetic and chemical perturbation. More than a dozen zebrafish mutants have been shown to recapitulate the characteristics of human hematological diseases, indicating that the hematopoietic system is highly conserved between zebrafish and humans. The proposed research will not only provide new insights into AML pathogenesis, but also lay a foundation for the use of zebrafish in studying the aging of the hematopoietic system. In addition, the proposed experiments will utilize novel chemical suppressors of the AML-like phenotype in zebrafish that we recently identified. Further characterization of these compounds may prove useful in the development of more effective and safer therapeutics against AML. The candidate has a background in cancer and molecular biology and now seeks to expand her scientific expertise and develop a research program centering around cancer, aging, and chemical biology. The candidate will conduct the research under the supervision of Dr. Randall Peterson. Dr. Peterson is known for his pioneering work on combining chemical genetic tools and zebrafish developmental biology for cardiovascular research. The candidate has also assembled a panel of advisors that include leaders in cancer, hemaotopoiesis, and aging. The sponsor and the advisors will closely interact with the candidate and guide her in both scientific and professional development. Ultimately, this program will facilitate the candidate's goals of becoming an independent investigator in cancer and aging.
描述(申请人提供):急性髓系白血病(AML)是一种在老年人中流行的致命疾病。不同于急性淋巴细胞白血病(ALL)的发病率在不同年龄段的人群中基本保持不变,AML的发病率随着年龄的增加而急剧增加,这表明年龄与AML的发病机制之间存在很强的相关性。这项拟议的研究旨在(1)确定在AML患者中发现的两种常见突变如何促进AML的发病;(2)确定导致AML发病的年龄相关因素;以及(3)验证潜在的、针对AML的新疗法。这些实验将利用各种独特的斑马鱼模型,使人类癌基因能够诱导表达。斑马鱼已经成为一种强大的脊椎动物模式生物,因为它高度容易受到遗传和化学干扰。十多个斑马鱼突变体被证明概括了人类血液病的特征,表明斑马鱼和人类之间的造血系统高度保守。本研究不仅为AML发病机制的研究提供了新的思路,也为利用斑马鱼研究造血系统的衰老奠定了基础。此外,拟议的实验将利用我们最近在斑马鱼中发现的AML样表型的新型化学抑制物。这些化合物的进一步表征可能有助于开发更有效和更安全的治疗急性髓细胞白血病的药物。这位候选人有癌症和分子生物学的背景,现在寻求扩大她的科学专长,并开发一个以癌症、衰老和化学生物学为中心的研究项目。候选人将在兰德尔·彼得森博士的监督下进行这项研究。彼得森博士以将化学遗传工具和斑马鱼发育生物学相结合用于心血管研究的开创性工作而闻名。这位候选人还组建了一个顾问小组,其中包括癌症、造血和老龄化方面的领导人。赞助商和顾问将与候选人密切互动,指导她在科学和专业方面的发展。最终,这项计划将促进候选人成为癌症和老龄化领域的独立调查员的目标。
项目成果
期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Efficient genome editing in zebrafish using a CRISPR-Cas system.
- DOI:10.1038/nbt.2501
- 发表时间:2013-03
- 期刊:
- 影响因子:46.9
- 作者:
- 通讯作者:
Highly efficient generation of heritable zebrafish gene mutations using homo- and heterodimeric TALENs.
- DOI:10.1093/nar/gks518
- 发表时间:2012-09
- 期刊:
- 影响因子:14.9
- 作者:Cade L;Reyon D;Hwang WY;Tsai SQ;Patel S;Khayter C;Joung JK;Sander JD;Peterson RT;Yeh JR
- 通讯作者:Yeh JR
Heritable and precise zebrafish genome editing using a CRISPR-Cas system.
- DOI:10.1371/journal.pone.0068708
- 发表时间:2013
- 期刊:
- 影响因子:3.7
- 作者:Hwang WY;Fu Y;Reyon D;Maeder ML;Kaini P;Sander JD;Joung JK;Peterson RT;Yeh JR
- 通讯作者:Yeh JR
Small zebrafish in a big chemical pond.
- DOI:10.1002/jcb.24120
- 发表时间:2012-07
- 期刊:
- 影响因子:4
- 作者:Helenius, I. Taneli;Yeh, J. -R. Joanna
- 通讯作者:Yeh, J. -R. Joanna
Zebrafish small molecule screen in reprogramming/cell fate modulation.
斑马鱼小分子筛选重编程/细胞命运调节。
- DOI:10.1007/978-1-60761-691-7_20
- 发表时间:2010
- 期刊:
- 影响因子:0
- 作者:Yeh,Jing-RueyJ;Munson,KathleenM
- 通讯作者:Munson,KathleenM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jing-Ruey Joanna Yeh其他文献
Jing-Ruey Joanna Yeh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jing-Ruey Joanna Yeh', 18)}}的其他基金
Targeting ROS production in OXPHOS-defective and OXPHOS-competent tumors
靶向 OXPHOS 缺陷型和 OXPHOS 功能型肿瘤中 ROS 的产生
- 批准号:
10322388 - 财政年份:2018
- 资助金额:
$ 13.26万 - 项目类别:
Targeting ROS production in OXPHOS-defective and OXPHOS-competent tumors
靶向 OXPHOS 缺陷型和 OXPHOS 功能型肿瘤中 ROS 的产生
- 批准号:
10063487 - 财政年份:2018
- 资助金额:
$ 13.26万 - 项目类别:
Discovering chemical tools for acute myelogenous leukemia
发现治疗急性髓性白血病的化学工具
- 批准号:
8462227 - 财政年份:2010
- 资助金额:
$ 13.26万 - 项目类别:
Discovering chemical tools for acute myelogenous leukemia
发现治疗急性髓性白血病的化学工具
- 批准号:
8103244 - 财政年份:2010
- 资助金额:
$ 13.26万 - 项目类别:
Discovering chemical tools for acute myelogenous leukemia
发现治疗急性髓性白血病的化学工具
- 批准号:
7939135 - 财政年份:2010
- 资助金额:
$ 13.26万 - 项目类别:
Discovering chemical tools for acute myelogenous leukemia
发现治疗急性髓性白血病的化学工具
- 批准号:
8657849 - 财政年份:2010
- 资助金额:
$ 13.26万 - 项目类别:
Discovering chemical tools for acute myelogenous leukemia
发现治疗急性髓性白血病的化学工具
- 批准号:
8248294 - 财政年份:2010
- 资助金额:
$ 13.26万 - 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
- 批准号:
7530462 - 财政年份:2008
- 资助金额:
$ 13.26万 - 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
- 批准号:
8134266 - 财政年份:2008
- 资助金额:
$ 13.26万 - 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
- 批准号:
7904815 - 财政年份:2008
- 资助金额:
$ 13.26万 - 项目类别:
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 13.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 13.26万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 13.26万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 13.26万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 13.26万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 13.26万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 13.26万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 13.26万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 13.26万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 13.26万 - 项目类别: